IMRX / Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for more_horizontal

IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effective more_horizontal

Immuneering Corporation (IMRX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares more_horizontal

Immuneering Corporation (IMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate rev more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 102.5% in Immuneering Corporation (IMRX). While the effective more_horizontal

Immuneering is a clinical-stage biopharmaceutical that focuses on oncology therapies. The company's lead therapy is in a phase 1/2a trial. more_horizontal

Immuneering Corporation (IMRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions mig more_horizontal